Home / Resource Library / Copanlisib in patients with relapsed or refractory indolent B-cell lymphoma: Primary results of the pivotal Chronos-1 study

Copanlisib in patients with relapsed or refractory indolent B-cell lymphoma: Primary results of the pivotal Chronos-1 study

Results of a phase II trial of copanlisib for relapsed/refractory indolent lymphoma.